Solco Healthcare

What Solco Healthcare does

Solco Healthcare is a private, for-profit pharmaceutical company founded in 2004 that operates in the medication delivery space. The firmographic record lists 11–50 employees and a website at solcohealthcare.com, though it carries a contradictory geographic footprint — "city: New Jersey" alongside "country: Trinidad and Tobago" — that the source material does not reconcile. Direct verification of its catalog was blocked: the website fetch returned only a "One moment, please… Please wait while your request is being verified" page, indicating an anti-bot/CDN gate that prevented inspection of the live product offering. As a result, the precise entity behind the brand, its registration jurisdiction, and its operational footprint cannot be substantiated from the supplied inputs.

The company's stated value proposition centers on sublingual drug delivery — formulations administered under the tongue — targeted at patients with cardiovascular disease and chronic pain conditions. This places Solco within the global sublingual drugs market, which a third-party industry projection sizes at US$8.7 billion in 2026, growing to US$15.0 billion by 2033 at an 8.0% CAGR, driven by the rising prevalence of cardiovascular and chronic pain conditions and by innovation in drug-delivery technologies. The firmographic source frames its primary functional offering as "high-quality medications" for these indications, but the input does not enumerate specific active pharmaceutical ingredients, dosage forms, branded or generic SKUs, pipeline assets, regulatory filings, or manufacturing capabilities, so the depth and width of the actual product portfolio cannot be characterized.

The business model is also under-documented. No pricing model, customer segmentation, go-to-market motion, distribution channel, or unit economics is disclosed. The company is privately held (IPO status: private) with no parent company, subsidiaries, mergers or acquisitions, funding rounds, management team, partnerships, awards, certifications, or strategic moves reported. Given the small employee count and the absence of any disclosed investor base, the operation is consistent with either an early-revenue specialty player or a sub-scale distributor. No revenue, ARR, or GMV figure is provided in the source material, and any revenue estimate carries Low confidence as a consequence.

Name

Solco Healthcare

Website

https://solcohealthcare.com

Company type

Private

Founded year

2004

Headcount range

11–50 employees

Short description

Solco Healthcare is a private pharmaceutical company founded in 2004, with 11–50 employees, that delivers medications via sublingual drug delivery technology. It serves patients with cardiovascular disease and chronic pain conditions through this specialized drug delivery approach.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pain Relief & Anti-Inflammatory (Analgesics) (HLAIADAA)

akta.pro secondary industry

OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief) (CRADAMAC)

Keywords

• Generic pharmaceuticals
• Sublingual medications
• Cardiovascular drugs
• Chronic pain therapy
• Drug delivery

Headquarters

HQ city

New Jersey

HQ country

Trinidad & Tobago

HQ region

Latin America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Core offering

Solco Healthcare is a pharmaceutical company dedicated to providing high-quality medications to its clients. Its offering is positioned within the sublingual drugs market, focusing on drug delivery formulations for cardiovascular and chronic pain conditions.

Differentiator

Problem solved

Functional benefit

Products and services

• High-quality medications (sublingual formulations) Sublingual pharmaceutical products targeting cardiovascular and chronic pain conditions, utilizing sublingual drug delivery technology for patient administration.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Broad incumbents

• Aurobindo Pharma: Aurobindo is a large Indian-headquartered generic manufacturer with an extensive oral solids portfolio including cardiovascular and pain products; it represents the broader global generic competition that pressures pricing for sublingual entrants.
• Sandoz (Novartis): Sandoz is a global generics leader with a deep cardiovascular and pain portfolio and growing investment in complex generics including alternative dosage forms; it anchors the competitive landscape Solco competes within.
• Teva Pharmaceutical Industries: Teva is the world's largest generic drug manufacturer with a broad portfolio including cardiovascular and pain generics; it is a broad incumbent competitor that defines the price and supply ceiling Solco must operate below.

Direct peers

• Endo International: Endo (Par Pharmaceutical) operates a large generic injectables and oral generics franchise focused on pain and cardiovascular conditions; it is a direct competitor for therapeutic generics that Solco also targets.
• Amneal Pharmaceuticals: Amneal is a U.S. generic and specialty pharma with a broad portfolio of oral and alternative dosage forms; it competes with Solco in generic cardiovascular and pain therapeutics and is a benchmark for specialty-generic expansion strategies.
• Indivior: Indivior's flagship Suboxone (buprenorphine/naloxone) is a sublingual product for opioid dependence; it is a direct delivery-format and therapeutic-area comparable, illustrating the commercial scale a sublingual platform can achieve.
• Collegium Pharmaceutical: Collegium specializes in sublingual and abuse-deterrent formulations for pain (e.g., BELBUCA), making it the most direct sublingual-delivery comparable for Solco's stated focus on chronic pain via sublingual dosage.
• Lannett Company: Lannett is a U.S. small-cap generic pharmaceutical manufacturer with a comparable product mix of oral solids and specialty generics; it is a direct comparable for a niche private generic manufacturer seeking scale in differentiated dosage forms.
• Upsher-Smith Laboratories: Upsher-Smith is a private U.S. generic pharmaceutical manufacturer of comparable size and product mix, including cardiovascular and pain medications; it is a structural and scale comparable for a niche private pharma.
• Prinston Pharmaceutical: Prinston Pharmaceutical is the closely related Solco Healthcare U.S. generics affiliate and shares product, manufacturing, and ownership lineage; it is the most direct functional peer for a generic pharma using sublingual and oral solid dose technology.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Solco Healthcare